放射源

Search documents
中国同辐(01763) - 於其他海外监管市场发佈的公告
2025-08-28 10:28
香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責,對其準確性 或完整性亦不發表任何聲明,並明確表示,概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 CHINA ISOTOPE & RADIATION CORPORATION 中國同輻股份有限公司 (於中華人民共和國註冊成立的股份有限公司) (股份代號:1763) 於其他海外監管市場發佈的公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條的規定而發出。 以下公告的中文原稿由中國同輻股份有限公司旗下一間於全國中小企業股份轉讓 系統上市的附屬公司,原子高科股份有限公司(股份代號:430005)於中國境內發 佈。 茲載列原子高科股份有限公司於2025年8月28日於全國中小企業股份轉讓系統網 站(www.neeq.com.cn)刊登的「原子高科股份有限公司2025年半年度報告」,僅供 參考。 承董事會命 中國同輻股份有限公司 董事長 肖亞飛 中國,北京,2025年8月28日 於本公告日期,董事會成員包括執行董事肖亞飛先生、張軍旗先生、霍穎穎女士 及馬曉宇女士;非執行董事陳贊先生、丁建民先生及 ...
中国同辐(01763.HK):放射源研发生产基地成功获批辐射安全许可证
Ge Long Hui· 2025-08-22 12:08
Core Viewpoint - China Tongfu (01763.HK) has successfully obtained a radiation safety license for its subsidiary Sichuan Nuclear Tongyuan Technology Co., Ltd., enabling it to produce and sell radiation sources, marking a significant step in its operational capabilities [1] Group 1: Project Overview - The project is the largest radiation source research and production base in Asia, featuring 13 production lines for various radiation sources including Carbon-14 and Krypton-85 [1] - Upon completion, the annual production capacity will exceed 100,000 radiation sources [1] Group 2: Product and Service Offerings - China Tongfu aims to consolidate domestic resources for the research and production of radiation sources, offering over 70 types of high-quality radionuclide products to both domestic and international markets [1] - The company will provide services for the reuse of radiation source resources and irradiation services, contributing positively to applications in industries such as agriculture, medicine, national defense, and aerospace [1] Group 3: Future Expansion Plans - The company plans to promote the second phase of the project with high standards to further expand production capacity and diversify its product offerings [1] - Future production lines will include isotopes such as Californium-252, Cesium-137, and Promethium-241 to meet diverse market demands [1]
中国同辐(01763) - 自愿性公告 - 中国同辐放射源研发生產基地成功获批辐射安全许可证
2025-08-22 11:52
香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責,對其準確性 或完整性亦不發表任何聲明,並明確表示,概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 自願性公告 CHINA ISOTOPE & RADIATION CORPORATION 中國同輻股份有限公司 (於中華人民共和國註冊成立的股份有限公司) (股份代號:1763) 中國同輻放射源研發生產基地成功獲批輻射安全許可證 本公告乃中國同輻股份有限公司(「中國同輻」或「本公司」)自願發出以使股東及潛 在投資者知悉本公司之最新業務進展。 本公司董事會欣然宣佈,近日,中國同輻旗下附屬公司四川中核同源科技有限公 司的放射源研發生產基地「該項目」成功獲批輻射安全許可證,正式具備放射源生 產、銷售等相關資質,產品將逐步面向市場。 該項目是亞洲最大的放射源研發生產基地,建設包括碳-14源、氪-85源等13條放 射源生產線,該項目建成後年產放射源將超過10萬枚。中國同輻將聚集國內主要 放射源的研發、生產資源,向國內外提供超過70種核素的高質量放射源產品,可 提供放射源資源再利用服務、輻照服務等,為我國工業、農業、 ...
中国同辐(01763):四〇四成都及成都核总拟向四川同源进行增资
智通财经网· 2025-03-28 16:24
Core Viewpoint - China Zhongfu (01763) announced that its subsidiary, China Nuclear High-Tech, signed a capital increase agreement with 404 Chengdu, Chengdu Nuclear General, and Sichuan Tongyuan, raising a total of RMB 2.35 million to enhance the registered capital of Sichuan Tongyuan from RMB 100 million to RMB 123 million [1][2] Group 1 - The capital increase agreement involves 404 Chengdu contributing RMB 12.3457 million and Chengdu Nuclear General contributing RMB 11.1111 million [1] - After the capital increase, China Nuclear High-Tech will hold 81% of Sichuan Tongyuan, while 404 Chengdu and Chengdu Nuclear General will hold 10% and 9%, respectively [1] - Sichuan Tongyuan, established in May 2019, is positioned as a world-class research and production base for radiation sources and is currently in the early stages of project construction and operational layout [1] Group 2 - The funds raised from the capital increase will be used to support the construction and operational funding of the radiation source research and production base project, which will help maintain a reasonable asset-liability structure for Sichuan Tongyuan [1] - The agreement aims to leverage the R&D and production advantages of the shareholders to achieve resource sharing and accelerate the localization of raw materials for radiation sources [2] - This collaboration is expected to create a stable supply chain for raw materials and enhance the industrial synergy among the shareholders, aligning with the overall interests of the company and its stakeholders [2]